April 15th 2025
To meet ambitious targets for ending the HIV/AIDS epidemic, governments must unite in a global effort to improve access to CD4 testing.
The Case for HIV Prevention and Screening: Pay Today or Pay Tomorrow
March 16th 2025Carl Schmid, executive director, HIV + Hepatitis Policy Institute, explains how a Supreme Court case could have far reaching implications for greater health screenings and preventative services beyond HIV and hepatitis.
Read More
Pandemic Disruptions in HIV Care Impacted on Early ART Initiation and Viral Suppression
March 13th 2025Sarita Shah, MD, MPH, reveals a decline in timely ART initiation from 86.5% in 2019 to 83.9% in 2020, with viral suppression rates dropping from 91.1% to 84.7%, before showing signs of recovery by 2021.
Read More
Doravirine and Islatravir Combination Shown to be Noninferior to Once-Daily ART
March 12th 2025In a blinded phase 3 study, doravirine and islatravir was compared to antiretroviral therapy, BIC/FTC/TAF (Biktarvy), and it was shown that there was no between-group differences in mean change in CD4 T-cell or total lymphocyte count at week 48.
Watch
The M&M Study: Age-Related T Cell Response in People with HIV on ART in MVA.HIVconsvX Vaccine Trial
March 10th 2025Nilu Goonetilleke, LLBHons, BScHons, presents findings from the phase 1 study, showing a 50% reduction in T cell response with age, while 85% of participants demonstrated strong immune responses.
Watch
Summarizing SGLT-2 Inhibitor Usage in People With Diabetes and HIV
January 16th 2025In persons living with HIV and diabetes, the management of diabetes is lagging behind the evidence. Despite SGLT-2 inhibitors demonstrating robust clinical data in the general population, they are grossly underused in persons with HIV and diabetes.
Read More
Black Women and HIV: Breaking Down Barriers, Having Conversations in the Communities
January 15th 2025There are high infection rates in this population, but limited opportunities to bring about awareness and education. However, a newer program sponsored by ViiV Healthcare looks to engage these women and bring about a better understanding behind transmission and care.
Watch
A Plea for New Guidance and Research: Low-Level Viremia in Persons Living With HIV
November 7th 2024Current guidelines and primary literature for managing persons living with HIV who have persistently low levels of HIV RNA are scarce. Considering the risks associated with this phenomenon, a call for further guidance and more robust studies are needed for these patients.
Read More
Twice-Yearly Lenacapavir May Change the World— If We Make It Work
November 3rd 2024Editor-in-Chief Jason Gallagher PharmD, FCCP, FIDP, FIDSA, BCPS discusses this agent as a potential tool for preexposure prophylaxis (PrEP) against HIV infection. And if it is approved, the ability to overcome access issues in low to middle income countries that have a greater need.
Read More
INSTIs and Cardiovascular Outcomes: More Complexity
October 28th 2024The significance of antiretroviral therapy (ART) has been a game changer for people living with HIV (PLWH). Still, there are some cardiovascular risks associated with different ART classes—particularly protease inhibitors (PIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and integrase strand transfer inhibitors (INSTIs). Authors review a piece in the literature around this area of study.
Read More
Long-Acting Injectable HIV Therapy: Addressing Adherence Challenges
October 21st 2024Elizabeth Hastie, MD discussed the LATITUDE trial results, highlighting the need for wider access to this treatment, especially for those not virally suppressed, and could help shape future healthcare guidelines.
Watch